Hansa Biopharma — September 2022
-
Hansa Biopharma - The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[
] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients -
-
Vil evt finansiering
ikke ske via royalty, og ikke emission med udvanding? -
@Jazz - Tænker at hvis tingene går som præsten prædiker det næste års tid, så laver de vel en tilsvarende finansieringsaftale, som de lige har lavet. Jo længere vi kommer hvor salgstallene udvikler sig som ventet og AMR m.m. skrider fremad desto nemmere må det være at lånefinansiere
-
"In 2020, we established an exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy in patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV)."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind